Taxanes in the elderly: can we gain as much and be less toxic?
Taxanes are very effective agents in several types of cancer. However, their activity is counterbalanced by side effects that could represent a limitation of their use in older cancer patients. This review aims at evaluating whether or not there are data supporting a tailored use of standard taxanes i.e. docetaxel and paclitaxel in elderly patients with the aim to increase their therapeutic index. In addition, recent data on the role of nanoparticle albumine-bound paclitaxel in breast cancer are discussed in this paper.
Biganzoli
Laura
L
Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Tuscany Cancer Institute, Piazza dell'Ospedale 2, 59100 Prato, Italy. lbiganzoli@usl4.toscana.it
Licitra
Sara
S
Moretti
Erica
E
Pestrin
Marta
M
Zafarana
Elena
E
Di Leo
Angelo
A